| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Air Pollution, Indoor | 14 | 2026 | 82 | 6.880 |
Why?
|
| Cooking | 15 | 2026 | 71 | 5.940 |
Why?
|
| Air Pollution | 12 | 2026 | 119 | 4.690 |
Why?
|
| Environmental Exposure | 12 | 2026 | 405 | 2.710 |
Why?
|
| Particulate Matter | 9 | 2026 | 138 | 2.460 |
Why?
|
| Air Pollutants | 7 | 2025 | 116 | 2.410 |
Why?
|
| Nigeria | 21 | 2026 | 174 | 2.260 |
Why?
|
| Asthma | 17 | 2025 | 1082 | 2.090 |
Why?
|
| Ethanol | 7 | 2022 | 282 | 1.460 |
Why?
|
| Pregnancy Outcome | 4 | 2023 | 284 | 1.230 |
Why?
|
| Hypertension | 5 | 2026 | 788 | 1.150 |
Why?
|
| Blood Pressure | 4 | 2025 | 920 | 1.140 |
Why?
|
| Pregnancy | 11 | 2023 | 3269 | 0.910 |
Why?
|
| Kerosene | 6 | 2022 | 18 | 0.890 |
Why?
|
| Smoke | 2 | 2016 | 29 | 0.860 |
Why?
|
| Fetal Development | 2 | 2022 | 37 | 0.850 |
Why?
|
| Maternal Exposure | 3 | 2022 | 69 | 0.830 |
Why?
|
| Gases | 1 | 2024 | 31 | 0.800 |
Why?
|
| Child Development | 1 | 2025 | 179 | 0.790 |
Why?
|
| Premature Birth | 2 | 2023 | 134 | 0.790 |
Why?
|
| Rural Population | 4 | 2017 | 193 | 0.720 |
Why?
|
| Female | 51 | 2026 | 51761 | 0.700 |
Why?
|
| Neoadjuvant Therapy | 2 | 2026 | 478 | 0.660 |
Why?
|
| Household Articles | 2 | 2017 | 17 | 0.650 |
Why?
|
| Cognition | 1 | 2025 | 669 | 0.640 |
Why?
|
| Humans | 70 | 2026 | 98370 | 0.630 |
Why?
|
| Biomarkers | 7 | 2026 | 2021 | 0.620 |
Why?
|
| Metals, Heavy | 1 | 2018 | 17 | 0.570 |
Why?
|
| Micronutrients | 1 | 2018 | 18 | 0.570 |
Why?
|
| Inflammation | 3 | 2016 | 1133 | 0.550 |
Why?
|
| Developing Countries | 4 | 2024 | 101 | 0.550 |
Why?
|
| Adult | 38 | 2026 | 29587 | 0.540 |
Why?
|
| Sleep Apnea, Obstructive | 4 | 2010 | 229 | 0.520 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2017 | 111 | 0.490 |
Why?
|
| Placenta Growth Factor | 1 | 2017 | 85 | 0.480 |
Why?
|
| Oxidative Stress | 2 | 2016 | 489 | 0.470 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2017 | 111 | 0.470 |
Why?
|
| Placenta | 1 | 2017 | 202 | 0.460 |
Why?
|
| Cross-Sectional Studies | 5 | 2025 | 2056 | 0.460 |
Why?
|
| Lung Diseases | 3 | 2014 | 284 | 0.450 |
Why?
|
| Family Characteristics | 3 | 2025 | 52 | 0.440 |
Why?
|
| Compassionate Use Trials | 1 | 2015 | 6 | 0.440 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2015 | 12 | 0.440 |
Why?
|
| Wood | 3 | 2021 | 23 | 0.430 |
Why?
|
| Epidemics | 1 | 2015 | 41 | 0.420 |
Why?
|
| Adolescent | 13 | 2026 | 10140 | 0.420 |
Why?
|
| Nasal Mucosa | 2 | 2025 | 194 | 0.410 |
Why?
|
| Breast Neoplasms | 4 | 2026 | 3285 | 0.410 |
Why?
|
| Male | 43 | 2026 | 47263 | 0.400 |
Why?
|
| Vaccines | 1 | 2015 | 86 | 0.400 |
Why?
|
| Trastuzumab | 2 | 2026 | 98 | 0.380 |
Why?
|
| Rescue Work | 1 | 2012 | 7 | 0.380 |
Why?
|
| Relief Work | 1 | 2012 | 8 | 0.380 |
Why?
|
| Inhalation Exposure | 1 | 2013 | 35 | 0.380 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2013 | 64 | 0.380 |
Why?
|
| Mass Casualty Incidents | 1 | 2012 | 14 | 0.370 |
Why?
|
| Earthquakes | 1 | 2012 | 14 | 0.370 |
Why?
|
| Altruism | 1 | 2012 | 35 | 0.370 |
Why?
|
| Disasters | 1 | 2012 | 25 | 0.370 |
Why?
|
| Hypoxia | 1 | 2017 | 682 | 0.370 |
Why?
|
| Ethics, Medical | 1 | 2015 | 292 | 0.360 |
Why?
|
| Antiviral Agents | 1 | 2015 | 369 | 0.350 |
Why?
|
| Child | 7 | 2025 | 7750 | 0.350 |
Why?
|
| Allergens | 1 | 2013 | 196 | 0.350 |
Why?
|
| Fetal Growth Retardation | 2 | 2022 | 73 | 0.340 |
Why?
|
| Income | 2 | 2024 | 101 | 0.340 |
Why?
|
| Ultrasonography, Prenatal | 2 | 2022 | 153 | 0.320 |
Why?
|
| Housing | 2 | 2021 | 51 | 0.310 |
Why?
|
| Young Adult | 7 | 2026 | 7568 | 0.310 |
Why?
|
| Immunoglobulin G | 2 | 2016 | 480 | 0.310 |
Why?
|
| Chicago | 5 | 2023 | 1519 | 0.310 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 408 | 0.300 |
Why?
|
| Vasoactive Intestinal Peptide | 3 | 2006 | 15 | 0.300 |
Why?
|
| Hypersensitivity | 1 | 2011 | 166 | 0.300 |
Why?
|
| Respiratory Sounds | 3 | 2017 | 40 | 0.300 |
Why?
|
| Infant, Newborn | 3 | 2023 | 2551 | 0.300 |
Why?
|
| Emergency Medical Services | 1 | 2012 | 286 | 0.280 |
Why?
|
| Gene Expression Regulation | 3 | 2025 | 2023 | 0.280 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2025 | 2579 | 0.270 |
Why?
|
| Obesity | 2 | 2014 | 1077 | 0.270 |
Why?
|
| Socioeconomic Factors | 4 | 2024 | 667 | 0.270 |
Why?
|
| Birth Weight | 2 | 2018 | 150 | 0.270 |
Why?
|
| Fetal Blood | 2 | 2018 | 95 | 0.260 |
Why?
|
| Logistic Models | 3 | 2017 | 1276 | 0.260 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2007 | 42 | 0.260 |
Why?
|
| Pentanes | 2 | 1997 | 4 | 0.260 |
Why?
|
| Lung | 5 | 2020 | 1408 | 0.260 |
Why?
|
| Gestational Age | 2 | 2018 | 342 | 0.250 |
Why?
|
| Community Participation | 2 | 2025 | 40 | 0.250 |
Why?
|
| Oxygen Consumption | 1 | 2007 | 239 | 0.250 |
Why?
|
| Cough | 2 | 2016 | 61 | 0.250 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2007 | 197 | 0.250 |
Why?
|
| Cardiovascular Diseases | 2 | 2024 | 822 | 0.240 |
Why?
|
| Middle Aged | 24 | 2026 | 29532 | 0.240 |
Why?
|
| Radon | 1 | 2025 | 8 | 0.230 |
Why?
|
| Stakeholder Participation | 1 | 2026 | 26 | 0.230 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2005 | 10 | 0.230 |
Why?
|
| Mouth | 1 | 2026 | 53 | 0.230 |
Why?
|
| Environmental Monitoring | 2 | 2017 | 93 | 0.220 |
Why?
|
| Autoantibodies | 1 | 2006 | 286 | 0.220 |
Why?
|
| Myocardial Infarction | 2 | 2025 | 396 | 0.220 |
Why?
|
| Health Policy | 1 | 2006 | 217 | 0.210 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2024 | 9 | 0.210 |
Why?
|
| Airway Obstruction | 1 | 2005 | 112 | 0.210 |
Why?
|
| Prevalence | 3 | 2023 | 1393 | 0.200 |
Why?
|
| Stillbirth | 1 | 2023 | 15 | 0.190 |
Why?
|
| Pregnancy Complications | 1 | 2006 | 369 | 0.190 |
Why?
|
| Arsenic Poisoning | 2 | 2014 | 104 | 0.190 |
Why?
|
| Risk Factors | 6 | 2025 | 6273 | 0.190 |
Why?
|
| Infant, Low Birth Weight | 1 | 2023 | 62 | 0.190 |
Why?
|
| Multifactorial Inheritance | 1 | 2025 | 236 | 0.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2026 | 2661 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2025 | 992 | 0.190 |
Why?
|
| Genome, Human | 2 | 2018 | 834 | 0.180 |
Why?
|
| Albuterol | 2 | 2000 | 37 | 0.180 |
Why?
|
| Adrenergic beta-Agonists | 2 | 2000 | 69 | 0.180 |
Why?
|
| Biometry | 1 | 2022 | 70 | 0.180 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2025 | 506 | 0.180 |
Why?
|
| Biomass | 2 | 2024 | 47 | 0.180 |
Why?
|
| Sleep Apnea Syndromes | 3 | 1997 | 109 | 0.180 |
Why?
|
| Poverty | 1 | 2024 | 214 | 0.180 |
Why?
|
| Gene Expression | 1 | 2025 | 1322 | 0.170 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2021 | 77 | 0.170 |
Why?
|
| Arsenic | 3 | 2020 | 294 | 0.170 |
Why?
|
| Oscillometry | 1 | 2020 | 24 | 0.160 |
Why?
|
| Thyroid Neoplasms | 1 | 2005 | 469 | 0.160 |
Why?
|
| Capacity Building | 2 | 2020 | 14 | 0.160 |
Why?
|
| Insulin | 1 | 2026 | 1224 | 0.160 |
Why?
|
| Breath Tests | 2 | 1997 | 60 | 0.160 |
Why?
|
| Gastroesophageal Reflux | 2 | 2009 | 129 | 0.160 |
Why?
|
| Laryngismus | 1 | 2000 | 3 | 0.160 |
Why?
|
| Interleukin-6 | 2 | 2023 | 283 | 0.160 |
Why?
|
| Edetic Acid | 1 | 2000 | 40 | 0.160 |
Why?
|
| Quality of Life | 4 | 2022 | 1899 | 0.160 |
Why?
|
| Fetus | 1 | 2021 | 238 | 0.160 |
Why?
|
| Bronchoconstriction | 1 | 2000 | 49 | 0.150 |
Why?
|
| Biomedical Research | 2 | 2016 | 471 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 195 | 0.150 |
Why?
|
| Microbiota | 1 | 2026 | 472 | 0.150 |
Why?
|
| Mouth Mucosa | 5 | 1997 | 71 | 0.150 |
Why?
|
| Age Factors | 2 | 2018 | 1974 | 0.150 |
Why?
|
| Depression | 1 | 2014 | 619 | 0.150 |
Why?
|
| DNA Methylation | 1 | 2024 | 735 | 0.150 |
Why?
|
| Body Weights and Measures | 1 | 2018 | 25 | 0.140 |
Why?
|
| Stroke | 2 | 2025 | 1167 | 0.140 |
Why?
|
| Serotonin Antagonists | 2 | 2010 | 24 | 0.140 |
Why?
|
| United States | 5 | 2025 | 8262 | 0.140 |
Why?
|
| Diltiazem | 1 | 1998 | 6 | 0.140 |
Why?
|
| Homologous Recombination | 1 | 2018 | 57 | 0.140 |
Why?
|
| Smoking | 2 | 2020 | 676 | 0.130 |
Why?
|
| Fever of Unknown Origin | 1 | 1997 | 5 | 0.130 |
Why?
|
| Giant Cell Arteritis | 1 | 1997 | 6 | 0.130 |
Why?
|
| Respiratory Function Tests | 3 | 2013 | 163 | 0.130 |
Why?
|
| Long QT Syndrome | 1 | 1998 | 38 | 0.130 |
Why?
|
| Vitamin D | 1 | 2020 | 286 | 0.130 |
Why?
|
| Mothers | 1 | 2018 | 149 | 0.130 |
Why?
|
| Carbon Monoxide | 1 | 2017 | 98 | 0.130 |
Why?
|
| Tobacco, Smokeless | 4 | 1997 | 11 | 0.130 |
Why?
|
| Polysomnography | 4 | 2010 | 154 | 0.130 |
Why?
|
| Plants, Toxic | 4 | 1997 | 23 | 0.130 |
Why?
|
| Household Products | 1 | 2016 | 9 | 0.120 |
Why?
|
| Biofuels | 1 | 2016 | 11 | 0.120 |
Why?
|
| Brain | 1 | 2007 | 2439 | 0.120 |
Why?
|
| Child, Preschool | 3 | 2020 | 4042 | 0.120 |
Why?
|
| Case-Control Studies | 3 | 2024 | 2009 | 0.120 |
Why?
|
| Piperidines | 1 | 1998 | 176 | 0.120 |
Why?
|
| Human Migration | 1 | 2016 | 31 | 0.120 |
Why?
|
| Antihypertensive Agents | 2 | 1998 | 273 | 0.120 |
Why?
|
| Morbidity | 1 | 2017 | 163 | 0.120 |
Why?
|
| Genetic Loci | 2 | 2019 | 263 | 0.120 |
Why?
|
| Molecular Epidemiology | 1 | 2016 | 57 | 0.120 |
Why?
|
| Pneumococcal Vaccines | 1 | 2016 | 32 | 0.120 |
Why?
|
| Bibliometrics | 1 | 2016 | 49 | 0.120 |
Why?
|
| Nitric Oxide | 1 | 1997 | 286 | 0.120 |
Why?
|
| International Cooperation | 2 | 2014 | 132 | 0.110 |
Why?
|
| Gene Flow | 1 | 2016 | 107 | 0.110 |
Why?
|
| Gastrointestinal Agents | 1 | 1998 | 202 | 0.110 |
Why?
|
| Antibodies, Bacterial | 1 | 2016 | 106 | 0.110 |
Why?
|
| Prospective Studies | 6 | 2023 | 4818 | 0.110 |
Why?
|
| Cryptogenic Organizing Pneumonia | 1 | 1995 | 5 | 0.110 |
Why?
|
| Africa, Western | 1 | 2015 | 12 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1126 | 0.110 |
Why?
|
| Resistin | 2 | 2026 | 16 | 0.110 |
Why?
|
| Ghrelin | 2 | 2026 | 31 | 0.110 |
Why?
|
| Aged | 10 | 2026 | 21844 | 0.110 |
Why?
|
| Ribonucleases | 1 | 1995 | 89 | 0.110 |
Why?
|
| World Health Organization | 1 | 2015 | 125 | 0.100 |
Why?
|
| Eosinophilia | 1 | 1995 | 87 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1010 | 0.100 |
Why?
|
| Eosinophils | 1 | 1995 | 196 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 1102 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2025 | 3228 | 0.100 |
Why?
|
| Anemia, Sickle Cell | 1 | 2016 | 158 | 0.100 |
Why?
|
| Respiration Disorders | 1 | 2013 | 42 | 0.100 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 1334 | 0.100 |
Why?
|
| Skin Tests | 1 | 2013 | 53 | 0.100 |
Why?
|
| Neprilysin | 3 | 1997 | 39 | 0.100 |
Why?
|
| Sex Factors | 1 | 2016 | 1142 | 0.090 |
Why?
|
| Dust | 1 | 2013 | 26 | 0.090 |
Why?
|
| Translating | 1 | 2012 | 17 | 0.090 |
Why?
|
| Haiti | 1 | 2012 | 23 | 0.090 |
Why?
|
| Oxidants | 1 | 2013 | 86 | 0.090 |
Why?
|
| Drinking Water | 1 | 2013 | 80 | 0.090 |
Why?
|
| Nutritional Status | 1 | 2013 | 84 | 0.090 |
Why?
|
| Volunteers | 1 | 2012 | 21 | 0.090 |
Why?
|
| Equipment and Supplies | 1 | 2012 | 32 | 0.090 |
Why?
|
| Immunoglobulin E | 1 | 2013 | 156 | 0.090 |
Why?
|
| Body Mass Index | 2 | 2014 | 867 | 0.090 |
Why?
|
| Lung Diseases, Obstructive | 1 | 1992 | 19 | 0.090 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 102 | 0.090 |
Why?
|
| Water Pollutants, Chemical | 1 | 2013 | 156 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 137 | 0.090 |
Why?
|
| Rural Health | 1 | 2011 | 18 | 0.090 |
Why?
|
| Antioxidants | 1 | 2013 | 236 | 0.090 |
Why?
|
| Urban Population | 1 | 2013 | 249 | 0.090 |
Why?
|
| Urban Health | 1 | 2011 | 54 | 0.080 |
Why?
|
| Respiratory Paralysis | 1 | 1991 | 9 | 0.080 |
Why?
|
| Bangladesh | 3 | 2020 | 361 | 0.080 |
Why?
|
| Exercise Therapy | 1 | 1992 | 97 | 0.080 |
Why?
|
| Heart Arrest, Induced | 1 | 1991 | 30 | 0.080 |
Why?
|
| Phrenic Nerve | 1 | 1991 | 49 | 0.080 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 198 | 0.080 |
Why?
|
| Feces | 1 | 2013 | 390 | 0.080 |
Why?
|
| Ondansetron | 1 | 2010 | 8 | 0.080 |
Why?
|
| Lung Diseases, Interstitial | 1 | 1995 | 331 | 0.080 |
Why?
|
| Hypothermia, Induced | 1 | 1991 | 94 | 0.080 |
Why?
|
| Fluoxetine | 1 | 2010 | 43 | 0.080 |
Why?
|
| Genomics | 1 | 2016 | 903 | 0.080 |
Why?
|
| Medical Oncology | 1 | 2014 | 423 | 0.080 |
Why?
|
| Dyspnea | 2 | 2005 | 90 | 0.080 |
Why?
|
| Patient Care Team | 1 | 2012 | 318 | 0.080 |
Why?
|
| Transcriptome | 2 | 2025 | 824 | 0.070 |
Why?
|
| Genome-Wide Association Study | 2 | 2019 | 1859 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2025 | 923 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2024 | 1296 | 0.070 |
Why?
|
| Hemoglobinometry | 1 | 2007 | 8 | 0.070 |
Why?
|
| Microcirculation | 3 | 1997 | 101 | 0.070 |
Why?
|
| Oxyhemoglobins | 1 | 2007 | 31 | 0.070 |
Why?
|
| Data Display | 1 | 2007 | 19 | 0.070 |
Why?
|
| Vasodilation | 3 | 1996 | 91 | 0.070 |
Why?
|
| Bronchoscopy | 1 | 1989 | 182 | 0.070 |
Why?
|
| Peptidyl-Dipeptidase A | 2 | 1997 | 35 | 0.070 |
Why?
|
| Hypoxia, Brain | 1 | 2007 | 41 | 0.060 |
Why?
|
| Mianserin | 1 | 2007 | 4 | 0.060 |
Why?
|
| Uvula | 2 | 1997 | 7 | 0.060 |
Why?
|
| Hemoglobins | 1 | 2007 | 198 | 0.060 |
Why?
|
| Anthropometry | 2 | 1997 | 77 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2013 | 3032 | 0.060 |
Why?
|
| Reference Values | 1 | 2007 | 608 | 0.060 |
Why?
|
| Neoplasms | 2 | 2020 | 3349 | 0.060 |
Why?
|
| Mutation | 1 | 2018 | 4428 | 0.060 |
Why?
|
| Cheek | 5 | 1997 | 19 | 0.060 |
Why?
|
| Regression Analysis | 1 | 2007 | 578 | 0.060 |
Why?
|
| Sleep Wake Disorders | 1 | 2008 | 139 | 0.060 |
Why?
|
| Hydrolysis | 1 | 2006 | 145 | 0.060 |
Why?
|
| Catalysis | 1 | 2006 | 216 | 0.060 |
Why?
|
| Face | 1 | 2006 | 116 | 0.060 |
Why?
|
| Intensive Care Units | 1 | 1989 | 474 | 0.060 |
Why?
|
| Tracheostomy | 1 | 2005 | 48 | 0.050 |
Why?
|
| Saliva | 1 | 2026 | 134 | 0.050 |
Why?
|
| Acute Disease | 2 | 1997 | 860 | 0.050 |
Why?
|
| Focus Groups | 1 | 2026 | 214 | 0.050 |
Why?
|
| Thyroidectomy | 1 | 2005 | 181 | 0.050 |
Why?
|
| Systole | 1 | 2024 | 81 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2001 | 1570 | 0.050 |
Why?
|
| Counseling | 1 | 2006 | 191 | 0.050 |
Why?
|
| Diastole | 1 | 2024 | 101 | 0.050 |
Why?
|
| Societies | 1 | 2024 | 16 | 0.050 |
Why?
|
| Skull | 1 | 2006 | 279 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2026 | 387 | 0.050 |
Why?
|
| Thinness | 1 | 2014 | 49 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2010 | 2017 | 0.050 |
Why?
|
| Universities | 2 | 2016 | 166 | 0.050 |
Why?
|
| Vital Capacity | 1 | 2014 | 74 | 0.050 |
Why?
|
| Forced Expiratory Volume | 1 | 2014 | 138 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2024 | 62 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2019 | 2574 | 0.050 |
Why?
|
| Cricetinae | 7 | 1997 | 533 | 0.050 |
Why?
|
| Fibronectins | 1 | 2024 | 104 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 1775 | 0.050 |
Why?
|
| Troponin | 1 | 2023 | 25 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2026 | 1195 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2026 | 415 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 1945 | 0.050 |
Why?
|
| C-Peptide | 1 | 2023 | 192 | 0.050 |
Why?
|
| Leptin | 1 | 2023 | 102 | 0.050 |
Why?
|
| Overweight | 1 | 2014 | 128 | 0.050 |
Why?
|
| Software | 1 | 2007 | 697 | 0.050 |
Why?
|
| Chronic Disease | 2 | 1997 | 988 | 0.050 |
Why?
|
| Bradykinin | 3 | 1997 | 45 | 0.050 |
Why?
|
| Exercise | 1 | 2006 | 382 | 0.050 |
Why?
|
| Consensus | 1 | 2024 | 309 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2006 | 419 | 0.050 |
Why?
|
| Mesocricetus | 6 | 1997 | 103 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2013 | 1947 | 0.050 |
Why?
|
| Arterioles | 3 | 1996 | 25 | 0.040 |
Why?
|
| Bronchodilator Agents | 2 | 2008 | 73 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2024 | 340 | 0.040 |
Why?
|
| Pulmonary Alveoli | 1 | 2001 | 71 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2024 | 244 | 0.040 |
Why?
|
| Scleroderma, Systemic | 1 | 2001 | 55 | 0.040 |
Why?
|
| Incidence | 1 | 2025 | 1787 | 0.040 |
Why?
|
| Respiratory Mechanics | 2 | 1992 | 109 | 0.040 |
Why?
|
| Models, Organizational | 1 | 2020 | 47 | 0.040 |
Why?
|
| Enzyme Inhibitors | 3 | 1998 | 642 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 713 | 0.040 |
Why?
|
| Double-Blind Method | 3 | 2010 | 1790 | 0.040 |
Why?
|
| Capillary Permeability | 2 | 1997 | 133 | 0.040 |
Why?
|
| Esomeprazole | 1 | 2009 | 2 | 0.040 |
Why?
|
| Anti-Ulcer Agents | 1 | 2009 | 22 | 0.040 |
Why?
|
| Administration, Inhalation | 1 | 2000 | 206 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2001 | 297 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2025 | 1568 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2026 | 11043 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2019 | 64 | 0.040 |
Why?
|
| APOBEC Deaminases | 1 | 2018 | 5 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2019 | 83 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2019 | 110 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2009 | 489 | 0.030 |
Why?
|
| Cisapride | 1 | 1998 | 4 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 83 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 1998 | 9 | 0.030 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 1998 | 41 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2009 | 265 | 0.030 |
Why?
|
| Exome | 1 | 2018 | 149 | 0.030 |
Why?
|
| Whole Genome Sequencing | 1 | 2018 | 121 | 0.030 |
Why?
|
| Mixed Function Oxygenases | 1 | 1998 | 68 | 0.030 |
Why?
|
| Drug Interactions | 1 | 1998 | 239 | 0.030 |
Why?
|
| Bronchitis | 1 | 1997 | 7 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2009 | 308 | 0.030 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 1997 | 10 | 0.030 |
Why?
|
| Cadherins | 1 | 2018 | 190 | 0.030 |
Why?
|
| DNA, Intergenic | 1 | 2016 | 28 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2018 | 484 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 1997 | 302 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2016 | 72 | 0.030 |
Why?
|
| Africa South of the Sahara | 1 | 2016 | 26 | 0.030 |
Why?
|
| Indomethacin | 4 | 1996 | 58 | 0.030 |
Why?
|
| Sexism | 1 | 2016 | 64 | 0.030 |
Why?
|
| Geography | 1 | 2016 | 249 | 0.030 |
Why?
|
| Substance P | 1 | 1995 | 62 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 463 | 0.030 |
Why?
|
| Peptides, Cyclic | 1 | 1995 | 43 | 0.030 |
Why?
|
| Eosinophil Granule Proteins | 1 | 1995 | 19 | 0.030 |
Why?
|
| Cell Degranulation | 1 | 1995 | 14 | 0.030 |
Why?
|
| Heart Rate | 1 | 1998 | 534 | 0.030 |
Why?
|
| Schools, Medical | 1 | 2016 | 135 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 917 | 0.030 |
Why?
|
| Thiophenes | 1 | 1995 | 46 | 0.030 |
Why?
|
| Salmeterol Xinafoate | 1 | 1994 | 16 | 0.030 |
Why?
|
| Vasoconstriction | 1 | 1995 | 88 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 578 | 0.030 |
Why?
|
| Blood Proteins | 1 | 1995 | 147 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1995 | 310 | 0.030 |
Why?
|
| Foundations | 1 | 2014 | 15 | 0.030 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2014 | 7 | 0.030 |
Why?
|
| International Agencies | 1 | 2014 | 35 | 0.030 |
Why?
|
| Government Agencies | 1 | 2014 | 13 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 1995 | 161 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2020 | 1791 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 1996 | 440 | 0.030 |
Why?
|
| Africa | 1 | 2014 | 113 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2014 | 75 | 0.030 |
Why?
|
| Areca | 1 | 2013 | 11 | 0.030 |
Why?
|
| Ethics, Research | 1 | 2014 | 54 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 1995 | 313 | 0.020 |
Why?
|
| Fluorescein-5-isothiocyanate | 3 | 1997 | 27 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 2014 | 97 | 0.020 |
Why?
|
| Dextrans | 3 | 1997 | 77 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2013 | 79 | 0.020 |
Why?
|
| Base Sequence | 1 | 2016 | 2224 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2013 | 221 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2013 | 127 | 0.020 |
Why?
|
| Nutrition Disorders | 1 | 1992 | 16 | 0.020 |
Why?
|
| Pulmonary Gas Exchange | 1 | 1992 | 37 | 0.020 |
Why?
|
| Respiratory Muscles | 1 | 1992 | 27 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1992 | 244 | 0.020 |
Why?
|
| Physical Fitness | 1 | 1992 | 55 | 0.020 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 1992 | 71 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 1995 | 7418 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 726 | 0.020 |
Why?
|
| Fatigue | 1 | 1992 | 187 | 0.020 |
Why?
|
| Skin | 1 | 2014 | 591 | 0.020 |
Why?
|
| Ventricular Function, Right | 1 | 1992 | 146 | 0.020 |
Why?
|
| Hospitalization | 1 | 1997 | 988 | 0.020 |
Why?
|
| Phylogeny | 1 | 2016 | 1340 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2013 | 1064 | 0.020 |
Why?
|
| Fiber Optic Technology | 1 | 1989 | 32 | 0.020 |
Why?
|
| Alleles | 1 | 2013 | 1163 | 0.020 |
Why?
|
| Bacteriological Techniques | 1 | 1989 | 39 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1989 | 136 | 0.020 |
Why?
|
| Coronary Artery Bypass | 1 | 1991 | 231 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 3361 | 0.020 |
Why?
|
| Cyclopropanes | 1 | 2008 | 26 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 765 | 0.020 |
Why?
|
| Theophylline | 1 | 2008 | 34 | 0.020 |
Why?
|
| Leukotriene Antagonists | 1 | 2008 | 24 | 0.020 |
Why?
|
| Intubation, Intratracheal | 1 | 1989 | 160 | 0.020 |
Why?
|
| Registries | 1 | 2014 | 1128 | 0.020 |
Why?
|
| Acetates | 1 | 2008 | 63 | 0.020 |
Why?
|
| Sulfides | 1 | 2008 | 72 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 1992 | 383 | 0.020 |
Why?
|
| Quinolines | 1 | 2008 | 97 | 0.020 |
Why?
|
| Thiorphan | 2 | 1997 | 5 | 0.020 |
Why?
|
| Glycopeptides | 2 | 1997 | 18 | 0.020 |
Why?
|
| Captopril | 2 | 1997 | 22 | 0.020 |
Why?
|
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2007 | 6 | 0.020 |
Why?
|
| Serotonin 5-HT3 Receptor Antagonists | 1 | 2007 | 3 | 0.020 |
Why?
|
| Protease Inhibitors | 2 | 1997 | 71 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 1997 | 99 | 0.020 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 1996 | 38 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2007 | 394 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2007 | 676 | 0.010 |
Why?
|
| Arginine | 2 | 1995 | 143 | 0.010 |
Why?
|
| Animals | 7 | 1997 | 28981 | 0.010 |
Why?
|
| Time Factors | 1 | 1991 | 5577 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 2001 | 65 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1991 | 2688 | 0.010 |
Why?
|
| Radiography | 1 | 2001 | 763 | 0.010 |
Why?
|
| Pulmonary Fibrosis | 1 | 2001 | 158 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2001 | 362 | 0.010 |
Why?
|
| Lisinopril | 1 | 1997 | 7 | 0.010 |
Why?
|
| Venules | 1 | 1996 | 6 | 0.010 |
Why?
|
| Diffusion Chambers, Culture | 1 | 1996 | 7 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1997 | 291 | 0.010 |
Why?
|
| Palate, Soft | 1 | 1996 | 5 | 0.010 |
Why?
|
| Superoxide Dismutase | 1 | 1997 | 155 | 0.010 |
Why?
|
| Muscle Tonus | 1 | 1996 | 16 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2010 | 9770 | 0.010 |
Why?
|
| Pharynx | 1 | 1996 | 43 | 0.010 |
Why?
|
| Hydrazines | 1 | 1996 | 36 | 0.010 |
Why?
|
| Rabbits | 1 | 1997 | 582 | 0.010 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 1996 | 29 | 0.010 |
Why?
|
| Epithelium | 1 | 1997 | 316 | 0.010 |
Why?
|
| Edema | 1 | 1996 | 68 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 1996 | 83 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1996 | 215 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1996 | 201 | 0.010 |
Why?
|
| Plasma Cells | 1 | 1996 | 91 | 0.010 |
Why?
|
| Calcimycin | 1 | 1995 | 32 | 0.010 |
Why?
|
| Ionophores | 1 | 1995 | 14 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 1996 | 133 | 0.010 |
Why?
|
| Capsaicin | 1 | 1995 | 43 | 0.010 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 1995 | 45 | 0.010 |
Why?
|
| Plasma | 1 | 1995 | 49 | 0.010 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 1996 | 112 | 0.010 |
Why?
|
| Nitroarginine | 1 | 1995 | 16 | 0.010 |
Why?
|
| Acrylates | 1 | 1995 | 16 | 0.010 |
Why?
|
| Allopurinol | 1 | 1995 | 77 | 0.010 |
Why?
|
| Plant Extracts | 1 | 1996 | 252 | 0.010 |
Why?
|
| Imidazoles | 1 | 1995 | 141 | 0.010 |
Why?
|